- Report
- July 2024
- 90 Pages
China
From €1616EUR$1,800USD£1,376GBP
- Report
- July 2024
- 326 Pages
China
From €3591EUR$4,000USD£3,058GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €8979EUR$10,000USD£7,646GBP
- Report
- November 2024
- 104 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- October 2024
- 85 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- February 2024
- 85 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- October 2023
- 92 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- November 2024
- 86 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- November 2024
- 90 Pages
Australia
From €1168EUR$1,301USD£995GBP
€1669EUR$1,859USD£1,421GBP
- Book
- February 2025
- 432 Pages
- Book
- March 2024
- 528 Pages
- Book
- February 2015
- 400 Pages
- Book
- January 2015
- 464 Pages
- Book
- August 2012
- 552 Pages
- Book
- November 2008
- 312 Pages
The Vaccine Adjuvant market is a subset of the Vaccines market, which is composed of products that are used to enhance the effectiveness of vaccines. Vaccine adjuvants are substances that are added to vaccines to increase the body's immune response to the vaccine. Adjuvants can be either natural or synthetic, and can be used to increase the potency of a vaccine, reduce the amount of antigen needed, or to extend the duration of the vaccine's effectiveness. Vaccine adjuvants are used in a variety of vaccines, including those for influenza, hepatitis, and human papillomavirus.
Some companies in the Vaccine Adjuvant market include GlaxoSmithKline, Merck, Sanofi, and Novartis. Show Less Read more
